Cannabis News
Latest UK medical cannabis news and updates
Budify.uk brings you the latest UK medical cannabis news, covering prescription changes, clinic updates, legislation, product launches, and patient advocacy. Our news feed is updated regularly to keep medical cannabis patients informed about developments that affect their treatment and access.
Why UK Employers Need a Medical Cannabis Policy
This article discusses the urgent need for UK employers to establish clear medical cannabis policies. It argues that without formal guidance, employers often rely on misconceptions regarding recreational drug use when managing employees using prescribed cannabis.
Read Full StoryTilray Medical Expands Medical Cannabis Access for Veterans Through Lyphe Clinic at Aldershot’s Armed Forces Weekend
Tilray Medical has expanded its 'Lyphe for Veterans' programme, which provides medical cannabis access to veterans residing in the UK and Channel Islands. The initiative was highlighted during Aldershot’s Armed Forces Weekend to improve healthcare support for the veteran community.
Read Full StoryHow Releaf became the first B Corp certified medical cannabis clinic
Releaf has become the first medical cannabis clinic globally to achieve B Corp certification, verified by the non-profit B Lab. This certification independently validates the clinic's commitment to high standards of social and environmental performance, transparency, and accountability.
Read Full StoryMedical Cannabis for ADHD in the UK: How It Compares With Stimulants
This report examines the growing interest in medical cannabis as an alternative or adjunct treatment for ADHD in the UK. It compares the efficacy and patient experience of cannabis-based medicines against traditional stimulant medications.
Read Full StoryMedical Cannabis for ADHD in the UK: How It Compares With Stimulants
This article explores the growing demand for medical cannabis as a treatment for ADHD in the UK. It examines how cannabis-based treatments compare to traditional stimulant medications in clinical practice.
Read Full StoryFSA Reassures CBD Sector as SPS Negotiations Continue
The UK Food Standards Agency (FSA) has issued a letter to stakeholders to clarify the potential impact of ongoing Sanitary and Phytosanitary (SPS) negotiations on the CBD sector. The move aims to provide reassurance to businesses operating within the UK market.
Read Full StoryNew Chapter for UK Medical Cannabis Policy
The Cannabis Industry Council has expressed optimism regarding the new UK government, led by Prime Minister Andy Burnham. The council is calling for evidence-led engagement to address ongoing barriers to patient access, prescribing, and research.
Read Full StoryUK Medical Cannabis Industry Calls for Long-Awaited ACMD Review
Industry stakeholders are closely monitoring the anticipated publication of the Advisory Council on the Misuse of Drugs (ACMD) report. The industry is pushing for this review to help modernize the regulatory landscape for medical cannabis.
Read Full StoryCancer Survivors and Providers Have Different Views on Medical Cannabis, Study Finds
A new study highlights a disconnect between cancer survivors and healthcare providers regarding the use of medical cannabis. The findings suggest a need for better communication and education to align expectations and clinical practice.
Read Full StoryCancer Survivors and Providers Have Different Views on Medical Cannabis, Study Finds
A recent study highlights a disconnect between cancer survivors and healthcare providers regarding the use of medical cannabis. The findings suggest differing perspectives on the efficacy and integration of cannabis into cancer care pathways.
Read Full StoryCancer Survivors and Providers Have Different Views on Medical Cannabis, Study Finds
A new study highlights significant discrepancies between cancer survivors and healthcare providers regarding the use of medical cannabis. The findings point to differing perceptions of risk, communication barriers, and varying levels of confidence in discussing cannabis within cancer care settings.
Read Full StoryNew Chapter for UK Medical Cannabis Policy
The Cannabis Industry Council has expressed optimism regarding the new UK government, calling for evidence-led engagement to address ongoing barriers to patient access and prescribing. The council aims to work with the new administration to improve the regulatory landscape for the sector.
Read Full StoryMeasuring What Matters: Why Outcomes Will Decide the Future of Cannabis Medicine
The UK medical cannabis sector is shifting its focus from the initial argument for access to a new phase centered on clinical outcomes. The article argues that patient-reported data and treatment efficacy will be the deciding factors for the future of the industry.
Read Full StoryBridging the Gap: Endometriosis and the Search for Better Symptom Management
This article explores the potential role of medical cannabis in managing symptoms for patients suffering from endometriosis. It highlights the ongoing search for more effective treatment options to improve quality of life for those affected by the condition.
Read Full StoryBridging the Gap: Endometriosis and the Search for Better Symptom Management
This feature explores the potential role of medical cannabis in managing symptoms for patients with endometriosis. It highlights the ongoing search for more effective treatment options for this chronic condition.
Read Full StoryNHS Trust Approves UK-First Inpatient Medical Cannabis Policy
Devon Partnership NHS Trust has implemented a landmark policy allowing patients to continue using legally prescribed medical cannabis while admitted as inpatients. This move aims to end the distress and confusion previously caused by staff uncertainty or the confiscation of legal medication.
Read Full StoryNHS Trust Approves UK-First Inpatient Medical Cannabis Policy
An NHS Trust has approved a landmark policy allowing for the use of medical cannabis in an inpatient setting. This development marks a significant shift in how NHS facilities approach the administration of cannabis-based medicines.
Read Full StoryAnanda Pharma Doses First Patient in NIHR-Backed CIPN Trial
Ananda Pharma has successfully dosed the first patient in a clinical trial supported by the National Institute for Health and Care Research (NIHR). The study focuses on treating Chemotherapy-Induced Peripheral Neuropathy (CIPN) using cannabinoid-based medicine.
Read Full StoryAnanda Pharma Doses First Patient in NIHR-Backed CIPN Trial
Ananda Pharma has successfully dosed the first patient in a clinical trial supported by the National Institute for Health and Care Research (NIHR). The study evaluates the effectiveness of an oral CBD-based solution for chemotherapy-induced peripheral neuropathy.
Read Full StoryCombination of THC and CBD Significantly Reduced Agitation in Late-Stage Dementia
A recent clinical trial has found that a combination of THC and CBD significantly reduced agitation in patients with late-stage dementia compared to a placebo. This study adds to the growing body of evidence for cannabinoid-based interventions in geriatric care.
Read Full StoryMedicinal Cannabis Matters: Friday Roundup - 10 July 2026
This roundup highlights a new peer-reviewed study in the journal Biomedicines showing positive patient outcomes for chronic conditions treated with medical cannabis. It also discusses the importance of employer awareness regarding prescribed cannabis in the workplace.
Read Full StoryBack pain patients see 'sustained' pain relief from inhaled cannabis, ceasing opioid use
A study indicates that chronic back pain patients achieved sustained pain relief through inhaled medical cannabis, with many successfully reducing or ceasing their use of opioid medications. The results reinforce growing evidence regarding cannabis as a potential substitute for traditional pain management therapies.
Read Full StoryMedical Cannabis at Work: Why Employers Need a Policy
As patient numbers rise, this article argues that UK employers must implement formal medical cannabis policies. It emphasizes the need for clear guidelines to protect both the employee and the business in accordance with current laws.
Read Full StoryAsk Umesh: HR has contacted my clinic, should I be worried?
This article addresses concerns regarding workplace interactions for medical cannabis patients in the UK. It provides guidance on legal rights and how to handle inquiries from employers regarding prescriptions.
Read Full StoryMedical cannabis access cuts number of sick days taken by employees
New research suggests that patients using medicinal cannabis may experience improved health outcomes, allowing them to take fewer sick days and maintain consistent employment. The findings highlight the potential for cannabis-based treatments to help individuals better manage chronic symptoms in a professional setting.
Read Full StoryCannabis Terpenes Show Promising Pain-Relieving Effects in New Study
New scientific research indicates that specific cannabis terpenes may offer pain-relieving properties. The study adds to the understanding of the 'entourage effect' and how non-cannabinoid compounds contribute to therapeutic outcomes.
Read Full StoryNine of the 10 Top CBPM Prescribers Are Pharmacists, UK FOI Data Shows
Recent Freedom of Information data highlights a significant shift in the medical cannabis landscape, showing that nine of the ten most frequent prescribers of cannabis-based products for medicinal use (CBPMs) are now pharmacists.
Read Full StoryUK Medical Cannabis Patient Numbers Set to Reach 140,000 in 2026, Industry Report Finds
A recent report from Prohibition Partners projects that the number of patients prescribed medical cannabis in the UK will surpass 140,000 by the end of 2026. The report highlights a significant increase in imports and product availability, with imports doubling in 2025 and the market potentially nearing £400 million by the end of the year.
Read Full StoryUK Medical Cannabis Imports and Product Availability Double, Market Could Near £400 Million in 2026, Finds Report
The UK's medical cannabis market is expanding rapidly, with imports and product availability more than doubling in a single year. Patient numbers are expected to surpass 140,000 by the end of 2026, with the market potentially nearing £400 million.
Read Full StoryUK Medical Cannabis Patient Numbers Set to Reach 140,000 in 2026, Industry Report Finds
A report by Prohibition Partners reveals that the number of UK medical cannabis patients is projected to exceed 140,000 by the end of 2026. The growth is driven by a massive increase in imports and a wider range of available cannabis-based medicines, primarily through the private sector.
Read Full StoryMedical cannabis prescriptions in London have more than doubled since 2021
Data from the NHS Open Data Portal reveals that medical cannabis prescriptions in London have increased by 105% since 2021, rising from 179 to 368 in 2025. Despite this growth, London remains the second-lowest region in the UK for cannabis-based medical prescriptions.
Read Full StoryCuraleaf Laboratories and Herdade das Barrocas (HDB) Announce Strategic Partnership to Reintroduce HDB Products to the UK Medical Cannabis Market
Curaleaf Laboratories and Portuguese cultivator Herdade das Barrocas have formed a strategic partnership to reintroduce HDB's cannabis products to the UK market. This collaboration aims to combine HDB's cultivation expertise with Curaleaf's manufacturing and distribution capabilities, enhancing the availability of medical cannabis in the UK.
Read Full StoryCannabis Commercialisation Not Decriminalisation Drives Up Usage, Study Finds
A recent study reveals that the commercialisation of cannabis supply, rather than decriminalisation, leads to increased usage and mental health issues. The review indicates that when cannabis is sold commercially, the number of users and instances of psychosis rise.
Read Full StoryThree arrested after record-breaking 12-tonne cannabis haul seized
Border Force officers seized a record 12-tonne shipment of cannabis worth £139 million at Southampton Port, leading to the arrest of three individuals on suspicion of facilitating importations.
Read Full StoryWegovy Weight-Loss Pills to Be Available for Patients in UK to Buy
The MHRA has approved Wegovy weight-loss pills for patient purchase in the UK, making it the third country to authorize the medication.
Read Full StoryCannabis-Based Drug Receives First European Market Approvals for Chronic Back Pain
Exilby®, a full-spectrum cannabis extract developed by German biopharmaceutical company Vertanical, has received market authorisation in Germany and Austria for the treatment of chronic lower back pain with a neuropathic component. UK approval is expected by the end of the year.
Read Full StoryMamedica
Mamedica is a London, UK-based medical cannabis clinic founded in 2021 and launched in 2022 by Jon Robson. It is one of four UK clinics licensed to prescribe and dispense medical cannabis. In August 2022, it published a survey of 4,000 people which found that 60% of British people would consider using cannabis to treat medical conditions, particularly if prescribed by a doctor.
Read Full StoryGlass Pharms
Glass Pharms is a UK-based medical cannabis cultivator known for its sustainable cultivation methods, including rainwater harvesting and vertical airflow regimes. In October 2024, it was reported that the facility’s annual production capacity was estimated to exceed 1,700 kg of medical cannabis flower. The company is among the first large-scale medical cannabis greenhouses in the UK.
Read Full StoryNHS Access to Medical Cannabis Could Unlock £13.3bn and Return Thousands to Work
Expanding NHS access to medical cannabis could help thousands of people with long-term health conditions return to work, while reducing hospital admissions for those eligible by 28% a year. Analysis shows it could add £4.5 billion to the economy over five years and £13.3 billion over a decade.
Read Full StoryThistle (drug consumption facility)
The Thistle is a drug consumption site in Glasgow, Scotland. It is the first and only legal drug consumption facility in Scotland or the United Kingdom. It opened on 13 January 2025. The facility is open 365 days a year from 9am to 9pm.
Read Full StoryNew UK Medical Cannabis Advocacy Group Launches
A new group, CannCare, has been launched in the UK to champion the rights of medical cannabis patients facing discrimination. Despite medical cannabis being legal in the UK for over six years, patients prescribed cannabis-based products for medicinal use (CBPM) can experience discrimination. CannCare's mission is to advocate for patients, taking on discrimination cases and fighting for patient rights.
Read Full StoryUK's Largest Medical Cannabis Deal Signed by Releaf
Releaf, the UK's fastest-growing medical cannabis provider, has signed a multi-million-pound contract with Glass Pharms, a leading domestic producer of medical cannabis. This partnership is the largest in the UK's medical cannabis sector to date, with Glass Pharms providing Releaf with 145kg of high-quality medical-grade cannabis. Releaf aims to become the largest medical cannabis provider in the UK within six months.
Read Full StoryMedical cannabis providers strike multimillion-pound deal set to “transform” distribution process
Medical cannabis providers Releaf and Glass Pharms have entered a 'historic' multimillion-pound partnership, which will see Glass Pharms provide Releaf with 145kg of high-quality medical-grade cannabis. The partnership aims to ensure a reliable and consistent UK-based supply chain of high-quality medical cannabis, addressing prescription reliability issues that have hindered the industry's maturation.
Read Full StoryUK's Largest Medical Cannabis Deal Signed by Releaf
Releaf, the UK's fastest-growing medical cannabis provider, has signed a multi-million-pound contract with Glass Pharms, a leading domestic producer of medical cannabis. This partnership is the largest in the UK's medical cannabis sector to date, with Glass Pharms providing Releaf with 145kg of high-quality medical-grade cannabis. Releaf aims to become the largest medical cannabis provider in the UK within six months.
Read Full StoryUK-based medical cannabis producer announces supplier agreement
Midlands-based medical cannabis producer Dalgety has announced a new contract agreement with Grow Pharma and its licensed JV partner IPS Pharma, enabling the commercial supply of pharmaceutical-grade, THC-rich prescription medicines to the UK market. The move positions Dalgety at the forefront of UK-based medical cannabis cultivation, with its first medicine made available by the end of 2023.
Read Full StoryReleaf Clinic Offers Industry First UK-Grown Medical Cannabis with Glass Pharms Partnership
Releaf, the UK's fastest-growing medical cannabis clinic, has announced a landmark partnership with Glass Pharms, a UK-based cannabis cultivator. This collaboration will introduce the first domestically grown, balanced, and THC-bearing medical cannabis flower to the UK market, available only through Releaf. The partnership aims to provide patients with a sustainable, high-quality, and consistent supply of medication.
Read Full StoryMilestone for UK first domestically grown medical cannabis
Medical cannabis cultivator Glass Pharms has officially delivered its first crop to the first UK-based clinic, marking the first time since medical cannabis was legalised that domestically grown product has been made available to patients. The launch of UK-grown medical cannabis marks a significant milestone in the development of the market, which has long been hamstrung by its reliance on imported products and its impact on supply chains.
Read Full StoryUK Patients Now Prescribed First Domestically Grown Medical Cannabis
Releaf, the UK's fastest-growing medical cannabis clinic, has announced a landmark partnership with Glass Pharms, a UK-based cannabis cultivator. This collaboration will introduce the first domestically grown, balanced, and THC-bearing medical cannabis flower to the UK market, available only through Releaf. The partnership aims to provide patients with a sustainable, high-quality, and consistent supply of medication.
Read Full StoryUK’s Medical Cannabis Boom: Patients, Demand and Consumption Surge to All-Time Highs - With a Record Number of Private Clinics
The UK is the primary driver of new growth in Europe’s medical cannabis market, with sales of medical cannabis greater than expected due to 'unusually high' consumption volumes on a per-patient basis. By the end of 2024, 62,960 patients are forecasted to be using medical cannabis in the UK, generating €240 million (£205 million) in sales.
Read Full StoryStill no medical cannabis trials for NHS - five years on from legalisation
Five years after medical cannabis was legalised in the UK, the government still hasn't funded clinical trials that could see it being used on the NHS. The Home Office reclassified the drug in 2018 to allow specialist doctors to prescribe it under tight controls. However, the National Institute for Health Research has not funded any studies on the safety and efficacy of cannabis since the law was changed.
Read Full Story